For example, the estrogen receptor partial agonist raloxifene was developed to avoid the side effects associated with endogenous estrogen in hormone replacement therapy.5 Raloxifene has a different spectrum of binding affinities for estrogen receptors in different tissues and thus provides therapeutic benefits of estrogen while minimizing adverse effects of the endogenous hormone.